Peter Lichter
Overview
Explore the profile of Peter Lichter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
343
Citations
36095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glaser S, Fischer A, Martinez-Manjon J, Lopez C, Kretzmer H, Burkhardt B, et al.
Leukemia
. 2025 Mar;
PMID: 40065077
No abstract available.
2.
Cheytan T, Schneider M, Wurth R, Schwerd-Kleine P, Gutjahr E, Thewes V, et al.
Mol Cancer
. 2025 Mar;
24(1):72.
PMID: 40057730
Metastatic breast cancer remains largely incurable, partly due to our incomplete understanding of its intricate underlying mechanisms. Notably, intercellular communication mediated by small extracellular vesicles and particles (sEVPs) has emerged...
3.
Schwerd-Kleine P, Wurth R, Cheytan T, Michel L, Thewes V, Gutjahr E, et al.
Int J Cancer
. 2025 Feb;
PMID: 40022208
The ability to establish organoids composed exclusively of tumour rather than healthy cells is essential for their implementation into clinical practice. Organoids have recently emerged as a powerful tool to...
4.
Roberti M, Charoentong P, Lyu Y, Meyer M, Eichmuller S, Schmidt P, et al.
Oncoimmunology
. 2025 Feb;
14(1):2457793.
PMID: 39902862
T cells that recognize tumor-specific mutations are crucial for cancer immunosurveillance and in adoptive transfer of TILs or transgenic-TCR T cell products. However, their challenging identification and isolation limits their...
5.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S, et al.
Nat Commun
. 2025 Jan;
16(1):1041.
PMID: 39863584
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model...
6.
Wurth R, Donato E, Michel L, Saini M, Becker L, Cheytan T, et al.
Nat Cancer
. 2025 Jan;
6(1):67-85.
PMID: 39753722
Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently...
7.
Man K, Wu Y, Gao Z, Spreng A, Keding J, Mangei J, et al.
EMBO Rep
. 2024 Sep;
25(11):5113-5140.
PMID: 39285246
Phenotypic plasticity is a cause of glioblastoma therapy failure. We previously showed that suppressing the oligodendrocyte-lineage regulator SOX10 promotes glioblastoma progression. Here, we analyze SOX10-mediated phenotypic plasticity and exploit it...
8.
Jager D, Berger A, Tuch A, Luckner-Minden C, Eurich R, Hlevnjak M, et al.
Clin Transl Med
. 2024 Jul;
14(7):e1776.
PMID: 39032146
No abstract available.
9.
Roessner P, Seufert I, Chapaprieta V, Jayabalan R, Briesch H, Massoni-Badosa R, et al.
Blood
. 2024 Apr;
144(5):510-524.
PMID: 38684038
The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted...
10.
Legrand C, Andriantsoa R, Lichter P, Raddatz G, Lyko F
PLoS Genet
. 2023 Dec;
19(12):e1011085.
PMID: 38096267
Clonal genome evolution is a key feature of asexually reproducing species and human cancer development. While many studies have described the landscapes of clonal genome evolution in cancer, few determine...